A Canadian MDMA production milestone has drawn attention to the next stage of psychedelic research. Here is what Phase 3 trials mean, how MDMA differs from psilocybin, and why approval is still not guaranteed.
Psilocybin research in Canada is expanding, but clinical trials are very different from casual mushroom use. Learn how studies work, what researchers measure, and how Canadians can interpret psychedelic claims responsibly.
Psilocybin Gummies: Ingredients, Health Risks and Legal Facts Psilocybin gummies are edible products described as containing psilocybin, a psychedelic compound found in certain mushroom species. However, a product name or package claim does not independently establish what a gummy contains. Some mushroom-labelled edibles contain different psychoactive substances, while others contain non-psychedelic mushroom ingredients. For readers […]
Albino Penis Envy: What Makes This Variety Different? Albino Penis Envy, often shortened to APE, is a named variety associated with Psilocybe cubensis. Its reputation centers on its pale appearance, distinctive shape, and claims about strength. Understanding those features requires separating visible characteristics from chemical measurements and medical evidence. A variety name can help organize […]
B+ Mushrooms: Background, Characteristics, and Common Questions B+ mushrooms are a familiar name in contemporary discussions of psilocybin-containing fungi. Commonly associated with Psilocybe cubensis, the label appears in mushroom literature, online conversations, and descriptions of cultivated varieties. However, familiarity does not establish a standardized biological identity, predictable potency, or a particular medical benefit. Claims that […]
By proceeding you affirm the statements above are true. This site uses cookies to remember your verification status. Privacy Policy.